Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 5/20 | 0.43 |
| ▸ | MMP13 | P45452 | 4/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | MMP7 | P09237 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | MMP14 | P50281 | 2/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | MMP10 | P09238 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409029 | 0.82 | MMP1 (0.50) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7303606 | 0.73 | MMP1 (0.43) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL6731754 | 0.71 | USP2 (0.47) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7305973 | 0.71 | MEN1 (0.43) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7308927 | 0.70 | MMP1 (0.50) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7304591 | 0.70 | MMP1 (0.64) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL9938067 | 0.70 | MMP1 (0.77) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7302178 | 0.69 | MMP1 (0.46) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL27463629 | 0.68 | MMP1 (0.47) | MMP1MMP13MMP2MMP3MMP7 | |
| Hydroxyamine SCHEMBL5914637 | 0.68 | MMP1 (0.74) | MMP1MMP13MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1357109-B1 | Process for aryl alkyl sulfide | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| EP-1357109-A2 | Process for aryl alkyl sulfide | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-29 | — | — | EP | disclosed |
| US-6518460-B2 | Antiinflammatory agents; cardiovascular disorders | SYNTEX (U.S.A.) LLC | 2003-02-11 | — | — | US | disclosed |
| CN-1388117-A | Process for prodcing 3-aryl sulfate iso-hydroximic acid | HOFFMANN LA ROCHE (CH) | 2003-01-01 | — | — | CN | disclosed |
| US-20020133030-A1 | Processes for preparing 3-arylsulfur hydroxamic acids | SYNTEX USA, LLC (US) | 2002-09-19 | — | — | US | disclosed |
| US-6420573-B1 | ALKYLATING A COMPOUND OF FORMULA II, RO-C( HORIZONTAL-LINE O)-CH(R1)(R2), WHERE R IS ALKYL OR HYDROGEN, WITH AN ARYLMETHYLTHIO COMOPUND; REPLACING GROUP RO-WITH XONX- AND OXIDIZING | SYNTEX (U.S.A.) LLP | 2002-07-16 | — | — | US | disclosed |
| US-20020038037-A1 | Processes for preparing 3-arylsulfur hydroxamic acids | SYNTEX (U.S.A.) INC. (US) | 2002-03-28 | — | — | US | disclosed |
| US-6342639-B1 | ENZYME INHIBITORS FOR PROTEOLYTIC ENZYMES | SYNTEX (U.S.A.) LLC | 2002-01-29 | — | — | US | disclosed |
| CN-1240208-A | Process for preparing 3-arylsulfur hydroxamic acids | HOFFMANN LA ROCHE (CH) | 2000-01-05 | — | — | CN | disclosed |
| EP-0965592-A1 | Process for preparing 3-arylsulfur hydroxamic acids | F. HOFFMANN-LA ROCHE AG (CH) | 1999-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038037-A1 | Processes for preparing 3-arylsulfur hydroxamic acids | HAX1, ARSA, PRDX1 | MMP1 4153/4885MMP13 4282/4885MMP2 4487/4885 |
| US-20020133030-A1 | Processes for preparing 3-arylsulfur hydroxamic acids | HAX1, ARSA, PRDX1 | MMP1 4153/4885MMP13 4282/4885MMP2 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.